# A Study to Compare the Pharmacokinetics and Safety/Tolerability of BR-UPS (Ulipristal Acetate) 5 mg Tablet With Inisia (Ulipristal Acetate) 5 mg Tablet

> **NCT03156127** · PHASE1 · WITHDRAWN · sponsor: **Boryung Pharmaceutical Co., Ltd**

## Conditions studied

- Uterine Myoma

## Interventions

- **DRUG:** BR-UPS 5 mg tablet, Inisia 5 mg tablet

## Key facts

- **NCT ID:** NCT03156127
- **Lead sponsor:** Boryung Pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2017-05-19
- **Primary completion:** 2017-07
- **Final completion:** 2017-10
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Problem of Investigational Products
- **Last updated:** 2017-08-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03156127

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03156127, "A Study to Compare the Pharmacokinetics and Safety/Tolerability of BR-UPS (Ulipristal Acetate) 5 mg Tablet With Inisia (Ulipristal Acetate) 5 mg Tablet". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03156127. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*